Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

Study of Emactuzumab for Tenosynovial Giant Cell Tumour (TGCT) is a phase 3 interventional study registered as NCT05417789, led by SynOx Therapeutics, and active but no longer recruiting when checked on 2026-09-11. Official title: A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour. Planned enrolment is 128 participants (estimated). The study started in 2024-10-09 and primary completion is expected in 2025-12-23. No results have been posted on ClinicalTrials.gov.